Johnson & Johnson (JNJ) 100.70 $JNJ As Biogen P
Post# of 64070
Posted On: 03/16/2015 2:00:25 PM
Johnson & Johnson (JNJ) 100.70 $JNJ
As Biogen Prepares to Reveal Alzheimer's Data, Expectations Are High
at The Street - 1 hr 45 mins ago
Biogen has added $25 billion in market value since the December -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.
JNJ: 100.70 (+1.49), BIIB: 420.40 (+7.05), PFE: 34.42 (+0.42), LLY: 71.08 (+1.19)
10 Great Stocks to Invest in for Your Retirement
Matthew Frankel, The Motley Fool - Motley Fool - Sun Mar 15, 5:08PM CDT
When you're saving up for your eventual retirement, know that some stocks make better investments than others. In a retirement account, you want stocks that will not only produce decades of growth and income but also preserve your hard-earned savings...
KO: 40.09 (+0.18), AXP: 81.37 (+0.77), XOM: 84.21 (+0.34), WMT: 83.15 (+1.25), WFC: 55.59 (+0.25), O: 50.55 (+0.50), GOOG: 556.19 (+8.87), JNJ: 100.70 (+1.49), GS: 191.97 (+2.63), TGT: 80.53 (+1.35), COST: 149.84 (+0.56), GOOGL: 562.79 (+9.79), PG: 83.24 (+1.41)
Dividend Champions: 15 Increases Expected By The End Of May
David Fish - at Seeking Alpha - Sun Mar 15, 12:15PM CDT
TNC: 65.45 (+0.73), XOM: 84.21 (+0.34), GWW: 233.45 (+2.73), MSA: 47.51 (-0.41), SRCE: 31.87 (-0.04), JNJ: 100.70 (+1.49), SON: 44.62 (+0.15), RLI: 51.55 (+1.30), FUL: 42.56 (-0.02), PG: 83.24 (+1.41), WEYS: 29.77 (+0.53), CVX: 102.46 (+0.84), NC: 52.77 (+2.68), PPG: 229.32 (+1.41), APD: 152.37 (+0.37)
Retirement Strategy: This Year The Ides Of March Are On My Side
Regarded Solutions - at Seeking Alpha - Sun Mar 15, 4:46AM CDT
KO: 40.09 (+0.18), F: 16.43 (+0.23), GE: 25.42 (+0.38), HCP: 40.72 (+0.53), ED: 61.77 (+0.93), XOM: 84.21 (+0.34), COP: 61.93 (+0.29), JNJ: 100.70 (+1.49), T: 32.99 (+0.23), PG: 83.24 (+1.41), CVX: 102.46 (+0.84), AAPL: 124.16 (+0.57), ORI: 15.22 (+0.24)
Nasdaq Dividend Achievers: Southern Company
Sure Dividend - at Seeking Alpha - Fri Mar 13, 11:51AM CDT
69.88 (+0.92), NEE: 103.49 (+2.88), JNJ: 100.70 (+1.49), ED: 61.77 (+0.93), SO: 44.54 (+0.59)
Bellwether Case over Ethicon Transvaginal Mesh Settles Mid-Trial, Parker Waichman LLP Comments
PRWeb - Fri Mar 13, 10:36AM CDT
Parker Waichman, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, is commenting on a recent settlement involving Ethicon's pelvic mesh device. Court documents show that a bellwether transvaginal mesh case was settled on the fifth day of trial. The lawsuit was filed on behalf of a woman who alleged that the device caused inflammation, chronic pain, and other injuries. She alleges that she underwent four surgeries to remove and revise the mesh implant, court records indicate. The case is Dianne M. Bellew v. Ethicon Inc., case number 2:13-cv-22473, in the U.S. District Court for the Southern District of West Virginia at Charleston.
JNJ: 100.70 (+1.49)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 256.05 (+1.07), CLDX: 30.86 (+1.12), EPZM: 22.36 (-0.66), STML: 16.20 (+0.19), JNJ: 100.70 (+1.49), ABBV: 58.85 (+0.85), INFI: 16.13 (+0.67), PTLA: 41.32 (+0.62), INCY: 90.90 (+1.59), PFE: 34.42 (+0.42), IMGN: 7.68 (-0.17), AMGN: 161.73 (+7.47), LLY: 71.08 (+1.19), BMY: 67.83 (+0.96), GSK: 46.92 (+0.55), SGEN: 39.07 (+0.76), GILD: 101.09 (+1.48), KITE: 63.53 (+0.44), MRK: 57.03 (+0.83), TEVA: 60.56 (+0.56), CELGZ: 3.02 (-0.03), KPTI: 30.67 (+2.59), NVS: 97.82 (+0.78)
Income Strategy: Can You Afford To Play It Safe?
Adam Aloisi - at Seeking Alpha - Fri Mar 13, 6:59AM CDT
KO: 40.09 (+0.18), T: 32.99 (+0.23), NLY: 10.53 (+0.03), JNJ: 100.70 (+1.49), ARCC: 16.85 (+0.01), PG: 83.24 (+1.41), O: 50.55 (+0.50), MORL: 19.78 (+0.12), EPD: 31.23 (+0.07)
Next Resistance Level for Johnson & Johnson (JNJ) is $100.40
Comtex SmarTrend(R) - Thu Mar 12, 9:45AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $98.79 and have already reached the first level of resistance at $99.36. Should the shares continue to rise, the resistance pivots of $100.40 and $102.01 will be of interest.
JNJ: 100.70 (+1.49)
US Wound Care Market Outlook and Trends 2015-2020
M2 - Thu Mar 12, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l7szr7/us_wound_care) has announced the addition of the "US Wound Care Market Outlook and Trends Till 2020" report to their offering. The Market Intelligence report provides critical market data for US wound care market and its product categories. The data includes market size in terms of value and volume; average selling price for each product type, growth trends and market shares of companies at sector and category level. It's vital cross category comparison and cross sub-category comparison section makes analysis very handy for company professionals. The report helps professionals in mapping market size, competition, understanding historic and future growth trends. It covers important categories such as traditional wound care, wound dressings, negative pressure wound therapy (NPWT), wound closure devices, ostomy bags, compression therapy. Wound Care Market Segmentation - Traditional Wound Care - Wound Dressings - Semi-Permeable Films - Foams - Alginates & Hydrofibres - Hydrocolloids - Hydrogels - Interactive Dressings - Collagens - Negative Pressure Wound Therapy (NPWT) - Wound Closure Devices - Hemostats - Tissue Sealants - Skin Closure Devices - Ostomy Bags - Compression Therapy Key Topics Covered: 1 Tables & Charts 2 Introduction 3 Scope of the Report 4 US Market for Wound Care (2007-2020) 5 US Market for Traditional Wound Care (2007-2020) 6 US Market for Wound Dressings (2007-2020) 7 US Market for Negative Pressure Wound Therapy (NPWT) (2007-2020) 8 US Market for Wound Closure Devices (2007-2020) 9 US Market for Ostomy (2007-2020) 10 US Market for Compression Therapy (2007-2020) 11 Recent Events and Developments 12 Appendix Companies Mentioned - 3M Health Care - Advanced Medical Solutions Group Plc - B. Braun Melsungen AG - Baxter International Inc. - BSN medical GmbH - Coloplast A/S - ConvaTec - Covidien Ltd. - Ethicon, Inc. - Hartmann Group - Hollister Incorporated - Johnson & Johnson - Kinetic Concepts, Inc. - Nycomed International Management GmbH - Smith & Nephew Plc For more information visit http://www.researchandmarkets.com/research/l7...wound_care
SNN: 34.00 (+0.50), JNJ: 100.70 (+1.49), BAX: 68.24 (+0.88), COV: 106.71 (-1.36)
DHR Proposes Blue Chip Roster of Board Candidates to CTPartners (NYSEMKT: CTP) Board of Directors, Increases Share Holdings
Business Wire - Wed Mar 11, 6:05PM CDT
Today, DHR International is proposing six new directors for election to the Board of Directors of CTPartners (NYSEMKT:CTP) and announced that DHR believes it is now the third largest shareholder in the company, holding approximately 7.3 percent of CTPartners' outstanding stock.
ABT: 47.72 (+0.84), GHL: 40.34 (+0.48), NKE: 96.31 (+0.50), GLW: 23.64 (+0.64), USTR: 39.28 (+0.46), JNJ: 100.70 (+1.49), WHR: 199.72 (+2.10), NTRS: 71.71 (+0.84), CTP: 6.89 (-0.36), VVI: 27.38 (-0.20)
Scott+Scott, Attorneys at Law, LLP Files Antitrust Class Action Against Disposable Contact Manufacturers
GlobeNewswire - Wed Mar 11, 4:53PM CDT
Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"
announces that it has filed a class action lawsuit on behalf of purchasers of disposable contact lenses alleging that certain manufacturers of contact lenses, including Defendants Alcon Laboratories, Inc. ("Alcon" (a division of Novartis International AG ("Novartis" ); Johnson & Johnson Vision Care, Inc. ("J&J" (which operates in the United States under the "Vistakon" trade name); Bausch + Lomb ("B&L" , owned by Valeant Pharmaceuticals, Inc. ("Valeant" ; and Cooper Vision, Inc. ("Cooper" (collectively, "Manufacturer Defendants" , conspired with each other and with Defendant ABB Optical Group ("ABB" to impose minimum resale prices on certain contact lens lines by subjecting them to a so-called "Unilateral Pricing Policy" ("UPP" and thereby eliminate price competition on those products.
JNJ: 100.70 (+1.49), NVS: 97.82 (+0.78)
I've Fallen In Love, With Dividends
Jack Banser - at Seeking Alpha - Wed Mar 11, 2:49PM CDT
KO: 40.09 (+0.18), T: 33.00 (+0.24), JNJ: 100.70 (+1.49), GE: 25.42 (+0.38), F: 16.43 (+0.23), MSEX: 22.37 (+0.08), AES: 12.03 (+0.11), AVA: 33.24 (+0.31), UFS: 44.25 (-0.22), QCOM: 69.32 (+0.68), PFE: 34.42 (+0.42), PG: 83.24 (+1.41), FLO: 21.39 (+0.31)
Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 2:31PM CDT
As per new data released from Express Scripts Holding Company (ESRX), new expensive HCV therapies coupled with the exploitation of loopholes for compounded medications, fuelled a phenomenal 13.1% surge in drug spending in the U.S. in 2014.
JNJ: 100.70 (+1.49), ESRX: 83.42 (+2.05), GILD: 101.09 (+1.48), ACHN: 11.21 (-0.09), ABBV: 58.85 (+0.85)
Jury Orders Johnson & Johnson to Pay $5.7M in Bellwether Case over Ethicon's TVT-Abbrevo Pelvic Mesh Device, Parker Waichman LLP Comments
PRWeb - Wed Mar 11, 12:31PM CDT
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, is commenting on the outcome of a bellwether trial involving a pelvic mesh lawsuit in California. Court documents show that a jury in Bakersfield ordered J&J to pay $5.7 million for injuries allegedly caused by Ethicon's TVT-Abbrevo pelvic mesh sling. The case is in the Superior Court of the State of California for the County of Kern; Coleen M. Perry, Plaintiff, vs. Hung T. Luu, M.D.; Johnson & Johnson, A New Jersey Corporation; Ethicon, Inc., A New Jersey Corporation; and DOES 1-60, Defendants; Case No.: 1500-Cv-279123 LHB; Assigned to the Honorable Lorna H. Brumfield; Reservation No.: 4676.
JNJ: 100.70 (+1.49)
5 Buy-Ranked Stocks Surviving the Slump - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Mar 11, 11:53AM CDT
Stocks closed at their lowest level in a month on Tuesday, weighed down by a surge in the dollar.
F: 16.43 (+0.23), G: 23.43 (+0.79), HSY: 100.50 (+0.62), SVU: 11.10 (+0.21), UTX: 119.59 (+0.85), OCN: 8.83 (-0.54), XOM: 84.21 (+0.34), HP: 63.62 (+1.13), JNJ: 100.70 (+1.49), PNK: 34.77 (+0.38), IBM: 156.15 (+1.87), EOG: 87.61 (+2.22), GM: 38.47 (+0.42), DD: 77.96 (-2.54), MRO: 25.82 (+0.04), PG: 83.24 (+1.41), CVX: 102.46 (+0.84), MSFT: 41.38 (unch)
Three ETFs Billionaire Ray Dalio Loves and Why You Should, Too
at The Street - Wed Mar 11, 11:09AM CDT
Nearly 90% of Ray Dalio's public equity portfolio is allocated to just three ETFs. What has the billionaire placing his eggs in these exchange-traded baskets?
JNJ: 100.70 (+1.49), EEM: 38.76 (+0.46), SPY: 208.07 (+2.24), XOM: 84.21 (+0.34), VWO: 39.67 (+0.47), BRK.B: 145.60 (+1.63), AAPL: 124.16 (+0.57)
Why Did Utilities Fall 10%? Are They Undervalued Now?
Sure Dividend - at Seeking Alpha - Wed Mar 11, 11:02AM CDT
WGL: 54.06 (+0.79), 69.88 (+0.92), KEP: 19.19 (+0.09), AWR: 40.92 (+0.75), PNY: 36.34 (+0.36), PCG: 53.84 (+2.04), ENI: 15.45 (-0.15), DUK: 75.83 (+1.22), MGEE: 43.20 (+0.68), PEG: 41.30 (+0.75), ED: 61.77 (+0.93), SRE: 108.05 (+1.69), AEP: 56.24 (+0.93), JNJ: 100.70 (+1.49), UGI: 32.30 (+0.52), SPY: 208.07 (+2.24), NWN: 45.77 (+0.71), VVC: 43.46 (+0.67), PPL: 32.28 (+0.48), TEG: 72.86 (+1.63), CWT: 25.10 (+0.29), BKH: 49.15 (+0.70), XEL: 34.27 (+0.53), STR: 23.08 (+0.22), EXC: 32.79 (+0.40), FE: 35.14 (+0.54), ATO: 53.84 (+0.75), HNP: 44.49 (+0.29), XLU: 44.28 (+0.80), DTE: 79.05 (+1.33), SO: 44.54 (+0.59), CTWS: 36.15 (-0.66), NEE: 103.49 (+2.88), MSEX: 22.37 (+0.08), ES: 49.91 (+0.78), SJW: 33.33 (+0.19), NGG: 63.25 (+0.11), OTTR: 32.31 (-0.06), EIX: 64.14 (+1.31)
Will Biogen Drug Score Big At Alzheimer's Conference?
at Investor's Business Daily - Wed Mar 11, 8:52AM CDT
A new research note from RBC Capital Markets offers a bullish take on Biogen Idec's (BIIB) experimental drug for Alzheimer's disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer's and Parkinson's...
JNJ: 100.70 (+1.49), BIIB: 420.40 (+7.05), GILD: 101.09 (+1.48), PFE: 34.42 (+0.42), AMGN: 161.73 (+7.47), LLY: 71.08 (+1.19), CELG: 120.31 (+2.58)
J & J's McNeil unit to pay $25M to settle federal probe
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 8:27AM CDT
JNJ: 100.70 (+1.49)
As Biogen Prepares to Reveal Alzheimer's Data, Expectations Are High
at The Street - 1 hr 45 mins ago
Biogen has added $25 billion in market value since the December -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.
JNJ: 100.70 (+1.49), BIIB: 420.40 (+7.05), PFE: 34.42 (+0.42), LLY: 71.08 (+1.19)
10 Great Stocks to Invest in for Your Retirement
Matthew Frankel, The Motley Fool - Motley Fool - Sun Mar 15, 5:08PM CDT
When you're saving up for your eventual retirement, know that some stocks make better investments than others. In a retirement account, you want stocks that will not only produce decades of growth and income but also preserve your hard-earned savings...
KO: 40.09 (+0.18), AXP: 81.37 (+0.77), XOM: 84.21 (+0.34), WMT: 83.15 (+1.25), WFC: 55.59 (+0.25), O: 50.55 (+0.50), GOOG: 556.19 (+8.87), JNJ: 100.70 (+1.49), GS: 191.97 (+2.63), TGT: 80.53 (+1.35), COST: 149.84 (+0.56), GOOGL: 562.79 (+9.79), PG: 83.24 (+1.41)
Dividend Champions: 15 Increases Expected By The End Of May
David Fish - at Seeking Alpha - Sun Mar 15, 12:15PM CDT
TNC: 65.45 (+0.73), XOM: 84.21 (+0.34), GWW: 233.45 (+2.73), MSA: 47.51 (-0.41), SRCE: 31.87 (-0.04), JNJ: 100.70 (+1.49), SON: 44.62 (+0.15), RLI: 51.55 (+1.30), FUL: 42.56 (-0.02), PG: 83.24 (+1.41), WEYS: 29.77 (+0.53), CVX: 102.46 (+0.84), NC: 52.77 (+2.68), PPG: 229.32 (+1.41), APD: 152.37 (+0.37)
Retirement Strategy: This Year The Ides Of March Are On My Side
Regarded Solutions - at Seeking Alpha - Sun Mar 15, 4:46AM CDT
KO: 40.09 (+0.18), F: 16.43 (+0.23), GE: 25.42 (+0.38), HCP: 40.72 (+0.53), ED: 61.77 (+0.93), XOM: 84.21 (+0.34), COP: 61.93 (+0.29), JNJ: 100.70 (+1.49), T: 32.99 (+0.23), PG: 83.24 (+1.41), CVX: 102.46 (+0.84), AAPL: 124.16 (+0.57), ORI: 15.22 (+0.24)
Nasdaq Dividend Achievers: Southern Company
Sure Dividend - at Seeking Alpha - Fri Mar 13, 11:51AM CDT
69.88 (+0.92), NEE: 103.49 (+2.88), JNJ: 100.70 (+1.49), ED: 61.77 (+0.93), SO: 44.54 (+0.59) Bellwether Case over Ethicon Transvaginal Mesh Settles Mid-Trial, Parker Waichman LLP Comments
PRWeb - Fri Mar 13, 10:36AM CDT
Parker Waichman, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, is commenting on a recent settlement involving Ethicon's pelvic mesh device. Court documents show that a bellwether transvaginal mesh case was settled on the fifth day of trial. The lawsuit was filed on behalf of a woman who alleged that the device caused inflammation, chronic pain, and other injuries. She alleges that she underwent four surgeries to remove and revise the mesh implant, court records indicate. The case is Dianne M. Bellew v. Ethicon Inc., case number 2:13-cv-22473, in the U.S. District Court for the Southern District of West Virginia at Charleston.
JNJ: 100.70 (+1.49)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 256.05 (+1.07), CLDX: 30.86 (+1.12), EPZM: 22.36 (-0.66), STML: 16.20 (+0.19), JNJ: 100.70 (+1.49), ABBV: 58.85 (+0.85), INFI: 16.13 (+0.67), PTLA: 41.32 (+0.62), INCY: 90.90 (+1.59), PFE: 34.42 (+0.42), IMGN: 7.68 (-0.17), AMGN: 161.73 (+7.47), LLY: 71.08 (+1.19), BMY: 67.83 (+0.96), GSK: 46.92 (+0.55), SGEN: 39.07 (+0.76), GILD: 101.09 (+1.48), KITE: 63.53 (+0.44), MRK: 57.03 (+0.83), TEVA: 60.56 (+0.56), CELGZ: 3.02 (-0.03), KPTI: 30.67 (+2.59), NVS: 97.82 (+0.78)
Income Strategy: Can You Afford To Play It Safe?
Adam Aloisi - at Seeking Alpha - Fri Mar 13, 6:59AM CDT
KO: 40.09 (+0.18), T: 32.99 (+0.23), NLY: 10.53 (+0.03), JNJ: 100.70 (+1.49), ARCC: 16.85 (+0.01), PG: 83.24 (+1.41), O: 50.55 (+0.50), MORL: 19.78 (+0.12), EPD: 31.23 (+0.07)
Next Resistance Level for Johnson & Johnson (JNJ) is $100.40
Comtex SmarTrend(R) - Thu Mar 12, 9:45AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $98.79 and have already reached the first level of resistance at $99.36. Should the shares continue to rise, the resistance pivots of $100.40 and $102.01 will be of interest.
JNJ: 100.70 (+1.49)
US Wound Care Market Outlook and Trends 2015-2020
M2 - Thu Mar 12, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l7szr7/us_wound_care) has announced the addition of the "US Wound Care Market Outlook and Trends Till 2020" report to their offering. The Market Intelligence report provides critical market data for US wound care market and its product categories. The data includes market size in terms of value and volume; average selling price for each product type, growth trends and market shares of companies at sector and category level. It's vital cross category comparison and cross sub-category comparison section makes analysis very handy for company professionals. The report helps professionals in mapping market size, competition, understanding historic and future growth trends. It covers important categories such as traditional wound care, wound dressings, negative pressure wound therapy (NPWT), wound closure devices, ostomy bags, compression therapy. Wound Care Market Segmentation - Traditional Wound Care - Wound Dressings - Semi-Permeable Films - Foams - Alginates & Hydrofibres - Hydrocolloids - Hydrogels - Interactive Dressings - Collagens - Negative Pressure Wound Therapy (NPWT) - Wound Closure Devices - Hemostats - Tissue Sealants - Skin Closure Devices - Ostomy Bags - Compression Therapy Key Topics Covered: 1 Tables & Charts 2 Introduction 3 Scope of the Report 4 US Market for Wound Care (2007-2020) 5 US Market for Traditional Wound Care (2007-2020) 6 US Market for Wound Dressings (2007-2020) 7 US Market for Negative Pressure Wound Therapy (NPWT) (2007-2020) 8 US Market for Wound Closure Devices (2007-2020) 9 US Market for Ostomy (2007-2020) 10 US Market for Compression Therapy (2007-2020) 11 Recent Events and Developments 12 Appendix Companies Mentioned - 3M Health Care - Advanced Medical Solutions Group Plc - B. Braun Melsungen AG - Baxter International Inc. - BSN medical GmbH - Coloplast A/S - ConvaTec - Covidien Ltd. - Ethicon, Inc. - Hartmann Group - Hollister Incorporated - Johnson & Johnson - Kinetic Concepts, Inc. - Nycomed International Management GmbH - Smith & Nephew Plc For more information visit http://www.researchandmarkets.com/research/l7...wound_care
SNN: 34.00 (+0.50), JNJ: 100.70 (+1.49), BAX: 68.24 (+0.88), COV: 106.71 (-1.36)
DHR Proposes Blue Chip Roster of Board Candidates to CTPartners (NYSEMKT: CTP) Board of Directors, Increases Share Holdings
Business Wire - Wed Mar 11, 6:05PM CDT
Today, DHR International is proposing six new directors for election to the Board of Directors of CTPartners (NYSEMKT:CTP) and announced that DHR believes it is now the third largest shareholder in the company, holding approximately 7.3 percent of CTPartners' outstanding stock.
ABT: 47.72 (+0.84), GHL: 40.34 (+0.48), NKE: 96.31 (+0.50), GLW: 23.64 (+0.64), USTR: 39.28 (+0.46), JNJ: 100.70 (+1.49), WHR: 199.72 (+2.10), NTRS: 71.71 (+0.84), CTP: 6.89 (-0.36), VVI: 27.38 (-0.20)
Scott+Scott, Attorneys at Law, LLP Files Antitrust Class Action Against Disposable Contact Manufacturers
GlobeNewswire - Wed Mar 11, 4:53PM CDT
Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"
announces that it has filed a class action lawsuit on behalf of purchasers of disposable contact lenses alleging that certain manufacturers of contact lenses, including Defendants Alcon Laboratories, Inc. ("Alcon" (a division of Novartis International AG ("Novartis" ); Johnson & Johnson Vision Care, Inc. ("J&J" (which operates in the United States under the "Vistakon" trade name); Bausch + Lomb ("B&L" , owned by Valeant Pharmaceuticals, Inc. ("Valeant" ; and Cooper Vision, Inc. ("Cooper" (collectively, "Manufacturer Defendants" , conspired with each other and with Defendant ABB Optical Group ("ABB" to impose minimum resale prices on certain contact lens lines by subjecting them to a so-called "Unilateral Pricing Policy" ("UPP" and thereby eliminate price competition on those products. JNJ: 100.70 (+1.49), NVS: 97.82 (+0.78)
I've Fallen In Love, With Dividends
Jack Banser - at Seeking Alpha - Wed Mar 11, 2:49PM CDT
KO: 40.09 (+0.18), T: 33.00 (+0.24), JNJ: 100.70 (+1.49), GE: 25.42 (+0.38), F: 16.43 (+0.23), MSEX: 22.37 (+0.08), AES: 12.03 (+0.11), AVA: 33.24 (+0.31), UFS: 44.25 (-0.22), QCOM: 69.32 (+0.68), PFE: 34.42 (+0.42), PG: 83.24 (+1.41), FLO: 21.39 (+0.31)
Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 2:31PM CDT
As per new data released from Express Scripts Holding Company (ESRX), new expensive HCV therapies coupled with the exploitation of loopholes for compounded medications, fuelled a phenomenal 13.1% surge in drug spending in the U.S. in 2014.
JNJ: 100.70 (+1.49), ESRX: 83.42 (+2.05), GILD: 101.09 (+1.48), ACHN: 11.21 (-0.09), ABBV: 58.85 (+0.85)
Jury Orders Johnson & Johnson to Pay $5.7M in Bellwether Case over Ethicon's TVT-Abbrevo Pelvic Mesh Device, Parker Waichman LLP Comments
PRWeb - Wed Mar 11, 12:31PM CDT
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, is commenting on the outcome of a bellwether trial involving a pelvic mesh lawsuit in California. Court documents show that a jury in Bakersfield ordered J&J to pay $5.7 million for injuries allegedly caused by Ethicon's TVT-Abbrevo pelvic mesh sling. The case is in the Superior Court of the State of California for the County of Kern; Coleen M. Perry, Plaintiff, vs. Hung T. Luu, M.D.; Johnson & Johnson, A New Jersey Corporation; Ethicon, Inc., A New Jersey Corporation; and DOES 1-60, Defendants; Case No.: 1500-Cv-279123 LHB; Assigned to the Honorable Lorna H. Brumfield; Reservation No.: 4676.
JNJ: 100.70 (+1.49)
5 Buy-Ranked Stocks Surviving the Slump - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Mar 11, 11:53AM CDT
Stocks closed at their lowest level in a month on Tuesday, weighed down by a surge in the dollar.
F: 16.43 (+0.23), G: 23.43 (+0.79), HSY: 100.50 (+0.62), SVU: 11.10 (+0.21), UTX: 119.59 (+0.85), OCN: 8.83 (-0.54), XOM: 84.21 (+0.34), HP: 63.62 (+1.13), JNJ: 100.70 (+1.49), PNK: 34.77 (+0.38), IBM: 156.15 (+1.87), EOG: 87.61 (+2.22), GM: 38.47 (+0.42), DD: 77.96 (-2.54), MRO: 25.82 (+0.04), PG: 83.24 (+1.41), CVX: 102.46 (+0.84), MSFT: 41.38 (unch)
Three ETFs Billionaire Ray Dalio Loves and Why You Should, Too
at The Street - Wed Mar 11, 11:09AM CDT
Nearly 90% of Ray Dalio's public equity portfolio is allocated to just three ETFs. What has the billionaire placing his eggs in these exchange-traded baskets?
JNJ: 100.70 (+1.49), EEM: 38.76 (+0.46), SPY: 208.07 (+2.24), XOM: 84.21 (+0.34), VWO: 39.67 (+0.47), BRK.B: 145.60 (+1.63), AAPL: 124.16 (+0.57)
Why Did Utilities Fall 10%? Are They Undervalued Now?
Sure Dividend - at Seeking Alpha - Wed Mar 11, 11:02AM CDT
WGL: 54.06 (+0.79),
69.88 (+0.92), KEP: 19.19 (+0.09), AWR: 40.92 (+0.75), PNY: 36.34 (+0.36), PCG: 53.84 (+2.04), ENI: 15.45 (-0.15), DUK: 75.83 (+1.22), MGEE: 43.20 (+0.68), PEG: 41.30 (+0.75), ED: 61.77 (+0.93), SRE: 108.05 (+1.69), AEP: 56.24 (+0.93), JNJ: 100.70 (+1.49), UGI: 32.30 (+0.52), SPY: 208.07 (+2.24), NWN: 45.77 (+0.71), VVC: 43.46 (+0.67), PPL: 32.28 (+0.48), TEG: 72.86 (+1.63), CWT: 25.10 (+0.29), BKH: 49.15 (+0.70), XEL: 34.27 (+0.53), STR: 23.08 (+0.22), EXC: 32.79 (+0.40), FE: 35.14 (+0.54), ATO: 53.84 (+0.75), HNP: 44.49 (+0.29), XLU: 44.28 (+0.80), DTE: 79.05 (+1.33), SO: 44.54 (+0.59), CTWS: 36.15 (-0.66), NEE: 103.49 (+2.88), MSEX: 22.37 (+0.08), ES: 49.91 (+0.78), SJW: 33.33 (+0.19), NGG: 63.25 (+0.11), OTTR: 32.31 (-0.06), EIX: 64.14 (+1.31) Will Biogen Drug Score Big At Alzheimer's Conference?
at Investor's Business Daily - Wed Mar 11, 8:52AM CDT
A new research note from RBC Capital Markets offers a bullish take on Biogen Idec's (BIIB) experimental drug for Alzheimer's disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer's and Parkinson's...
JNJ: 100.70 (+1.49), BIIB: 420.40 (+7.05), GILD: 101.09 (+1.48), PFE: 34.42 (+0.42), AMGN: 161.73 (+7.47), LLY: 71.08 (+1.19), CELG: 120.31 (+2.58)
J & J's McNeil unit to pay $25M to settle federal probe
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 8:27AM CDT
JNJ: 100.70 (+1.49)
(0)
(0)Scroll down for more posts ▼